Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

In 30 seconds

The phase 3 explorer8 study evaluated concizumab, a nonfactor replacement therapy, in males aged ≥12 years with hemophilia A or B without inhibitors. At the 56-week cutoff, concizumab demonstrated superior efficacy compared to on-demand treatment, with median annualized bleeding rates of 1.7 for hemophilia A and 2.8 for hemophilia B, indicating sustained low bleeding episodes.

Key findings

• Median annualized bleeding rate for hemophilia A was 1.7 (IQR, 0.0-4.5) at 56 weeks.
• Median annualized bleeding rate for hemophilia B was 2.8 (IQR, 0.0-6.4) at 56 weeks.
• Concizumab was well tolerated with no new safety concerns reported.
• 17 patients switched from no prophylaxis to concizumab after ≥24 weeks of treatment.

Why it matters

Concizumab offers a promising prophylactic treatment option for patients with hemophilia A and B without inhibitors, potentially reducing bleeding episodes and improving quality of life. Understanding its long-term efficacy and safety is crucial for clinicians managing these patients.